Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1835 results
December 2018
-
Press Release
Novartis receives European Commission (EC) approval for expanded indication for Kisqali® (ribociclib)
Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali® (ribociclib), the CDK4/6 inhibitor with the largest body of… -
Press Release
Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies
Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah® (tisagenlecleucel) and recent successful completion of… -
Key Release
Novartis announces new CEO of Oncology Business Unit
Susanne Schaffert, Ph.D., President, AAA, an established Novartis executive, named new CEO, Novartis Oncology Basel, December 20, 2018 - Novartis announced today that Susanne Schaffert, Ph.D.,… -
Press Release
Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises
Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart Over 400 million people worldwide have… -
Press Release
Alcon Announces Acquisition of Tear Film Innovations, Inc.
Acquisition further expands Alcon's portfolio of comprehensive solutions for patients with dry eye Tear Film's iLux® Device offers innovative, customizable treatment for Meibomian Gland… -
Press Release
Novartis receives European Commission approval for self-administration of Xolair® across all indications
The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe[1] Xolair® (omalizumab) prefilled… -
Story Discovery
Women in Science: Susanne Schaffert
Susanne Schaffert, President of Advanced Accelerator Applications, describes her career in science.
-
Story Discovery
Bringing real change to people
An interview with Thierry Diagana, Head of the Novartis Institute for Tropical Diseases.
-
Press Release
Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder
reSET-OTM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two… -
Story Patient Perspectives
The changing landscape of cancer treatment
-
Press Release
Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine… -
Story Access to Healthcare
Improving lives through community-based care
Bringing healthcare closer to where people live, work and shop can effectively tackle hypertension – the most deadly noncommunicable disease.